When it comes to payer marketing, the people pharma want to reach are digital-savvy researchers who prefer to get info online, new research has found.

How many prescriptions does it take to find the right antidepressant? J&J's Healthy Minds video series tackles that question.

Eli Lilly is counting on psoriasis med Taltz to drive U.S. volume growth. But lately, that growth has stalled.

Horizon has thrown more commercial heft behind long-troubled gout med Krystexxa, thanks to promising early results from a tweaked sales pitch.

Flexion's raring to launch its knee injection Zilretta, and it's floating a $100 million-plus stock offering to make that happen.

A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.

Two new Novo Nordisk ads seem to be typical pharma company spots with middle-aged couples strolling happily along, until they aren't.

Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.